The association between nirmatrelvir therapy and COVID-19–related hospitalization or death was estimated with the use of a multivariate Cox proportional–hazards regression model after adjustment for confounding factors
| Variable . | HR for COVID-19–related hospitalization or death . | P value . |
|---|---|---|
| Age | 1.05 (1.03-1.07) | <.001∗ |
| Number of previous CLL treatments | 1.39 (1.17-1.65) | <.001∗ |
| Recent hospitalizations† | 1.92 (1.25-2.95) | .0027‡ |
| IVIG treatment | 1.96 (1.2-3.4) | .019§ |
| Nirmatrelvir | 0.48 (0.13-0.63) | .002‡ |
| Previous COVID-19 infection | 0.22 (0.07-0.72) | .0199§ |
| Doses of COVID-19 vaccine|| before infection | 0.75 (0.63-0.89) | <.001∗ |
| Recent melanoma† | 1.79 (1.09-2.94) | .0213§ |
| Recent other malignancy† | 0.42 (0.19-0.91) | .0284§ |
| Asthma | 2.66 (1.22-5.81) | .0141§ |
| Myeloproliferative diseases | 3.19 (1.58-6.43) | .0012‡ |
| Chronic kidney disease status | 1.1 (0.62-1.95) | .667 |
| Variable . | HR for COVID-19–related hospitalization or death . | P value . |
|---|---|---|
| Age | 1.05 (1.03-1.07) | <.001∗ |
| Number of previous CLL treatments | 1.39 (1.17-1.65) | <.001∗ |
| Recent hospitalizations† | 1.92 (1.25-2.95) | .0027‡ |
| IVIG treatment | 1.96 (1.2-3.4) | .019§ |
| Nirmatrelvir | 0.48 (0.13-0.63) | .002‡ |
| Previous COVID-19 infection | 0.22 (0.07-0.72) | .0199§ |
| Doses of COVID-19 vaccine|| before infection | 0.75 (0.63-0.89) | <.001∗ |
| Recent melanoma† | 1.79 (1.09-2.94) | .0213§ |
| Recent other malignancy† | 0.42 (0.19-0.91) | .0284§ |
| Asthma | 2.66 (1.22-5.81) | .0141§ |
| Myeloproliferative diseases | 3.19 (1.58-6.43) | .0012‡ |
| Chronic kidney disease status | 1.1 (0.62-1.95) | .667 |
Variables that met the testing criteria and were significantly associated with the outcome served as the inputs for the multivariate regression analysis. IVIG, intravenous immunoglobulin.
Very highly statistically significant at the level 0.001
Recent refers to last 3 years.
Highly statistically significant at the level 0.01
Statistically significant at the level 0.05
Number of doses counts both messenger RNA–based vaccines (mainly Pfizer) and passive vaccines (75 patients received tixagevimab and cilgavimab).